Design, synthesis and anti-malarial activities of synthetic analogs of biselyngbyolide B, a Ca2+ pump inhibitor from marine cyanobacteria

  • Bioorg Med Chem Lett. 2018 Feb 1;28(3):298-301. doi: 10.1016/j.bmcl.2017.12.050.
Eisuke Sato  1 Maho Morita  2 Haruo Ogawa  3 Masato Iwatsuki  4 Rei Hokari  4 Aki Ishiyama  4 Satoshi Ōmura  4 Arihiro Iwasaki  1 Kiyotake Suenaga  5
Affiliations
  • 1. Department of Chemistry, Faculty of Science and Technology, Keio University, Hiyoshi 3-14-1, Kohoku-ku, Yokohama 223-8522, Japan.
  • 2. Department of Chemistry, Faculty of Science and Technology, Keio University, Hiyoshi 3-14-1, Kohoku-ku, Yokohama 223-8522, Japan; Institute of Molecular and Cellular Bioscience, The University of Tokyo, Bunkyo-ku, Tokyo 113-0032, Japan.
  • 3. Institute of Molecular and Cellular Bioscience, The University of Tokyo, Bunkyo-ku, Tokyo 113-0032, Japan.
  • 4. Research Center for Tropical Diseases, Kitasato Institute for Life Science, and Graduate School of Infection Control Science, Kitasato University, 5-9-1, Shirokane Minato-ku, Tokyo 108-8641, Japan.
  • 5. Department of Chemistry, Faculty of Science and Technology, Keio University, Hiyoshi 3-14-1, Kohoku-ku, Yokohama 223-8522, Japan. Electronic address: [email protected].
Abstract

Biselyngbyaside, an 18-membered Macrolide glycoside from marine cyanobacteria, and its derivatives are known to be sarco/endoplasmic reticulum CA2+ ATPase (SERCA) inhibitors. Recently, a SERCA orthologue of the malaria Parasite, PfATP6, has attracted attention as a malarial drug target. To provide a novel drug lead, we designed new synthetic analogs of biselyngbyolide B, the aglycone of biselyngbyaside, based on the co-crystal structure of SERCA with biselyngbyolide B, and synthesized them using the established synthetic route for biselyngbyolide B. Their biological activities against malarial parasites were evaluated.

Keywords
Biselyngbyaside; Biselyngbyolide; PfATP6; SERCA; Structure–activity relationships.
Products